Eric Halioua

Eric Halioua is a prominent figure in the biotechnology and life sciences industry, currently serving as a Board Member at essenscia, specifically for bio.be/essenscia, the Belgian federation of companies active in life sciences and biotechnologies.13

Professional Background

Eric Halioua is a serial entrepreneur with extensive experience in strategic, technological, and managerial aspects of the biotech industry. His career highlights include:

Current Positions:

• President and CEO of PDC*line Pharma, a biotechnology company12
• Board Member at essenscia (bio.be) since January 20211
• Founder and Managing Partner of CarKath sprl, offering strategic advisory and corporate finance services for the Life Sciences industry1

Past Roles:

• Co-founder and CEO of Digital Orthopaedics (2016-2019)1
• CEO of Promethera Biosciences (2009-2015)1
• Board Director at European Biopharmaceutical Enterprises (2013-2015)1
• Co-founder and CEO of MYOSIX (1999-2002), which was later acquired by Genzyme1

Achievements and Expertise

Eric Halioua has a proven track record in:

• Bringing drug candidates from research to clinical trials (up to phase IIb)1
• Fundraising, having raised over €160 million from VCs and strategic partners across Europe, USA, Japan, and Korea1
• Deal-making and successful exits, including sales and initial public offerings of biotechnology companies1

Education

Halioua holds:

• Two master's degrees in pharmacology and Molecular Biology
• An MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair2

Eric Halioua's LinkedIn username is indeed "halioua", as mentioned in the query.1